AndreaBozzo/ceres-open-data-index huggingface dataset:
Preferences of Mexican anesthesiologists for vecuronium, rocuronium, or other neuromuscular blocking agents: a survey

Background
          Several neuromuscular blocking (NMB) agents are available for clinical use in anesthesia. The present study was performed in order to identify preferences and behaviors of anesthesiologists for using vecuronium, rocuronium or other NMB agents in their clinical practice.
        
        
          Material and methods
          The cross-sectional survey was applied at the Updated Course of the Colegio Mexicano de Anestesiología performed last year. Of 989, 282 (28.5%) surveys were returned.
        
        
          Results
          Most anesthesiologists were working at both public and private hospitals, performed anesthetic procedures for hospitalized and ambulatory patients, and anesthetized children as well as adults. Respondents did not consider mechanomyography as the gold standard method for neuromuscular monitoring. The T25 was not recognized as a pharmacodynamic parameter that represents the clinical duration of the neuromuscular block. Most answered that vecuronium induces less histamine release than rocuronium, had never used any neuromuscular monitor, did not know the cost of vecuronium and rocuronium, and preferred rocuronium in multiple-sampling vials and vecuronium in either a vial for single or multiple sampling. Rocuronium was preferred for emergency surgery in patients with full stomach only. Almost all of anesthesiologists that conserve the unused drug did it without refrigeration and more than 30% conserve the unused drug in one syringe for further use.
        
        
          Conclusion
          Vecuronium was preferred for most clinical situations, and the decision for this choice was not based on costs. Storage of unused drugs without refrigeration in a single syringe for purpose of future use in several patients represented a dangerous common practice.
Compound 525281: N'-Isobutyl-N,N-dimethyl-acetamidine

Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(2-methylpropyl)ethanimidamide. Molecular Formula: C8H18N2. Molecular Weight: 142.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529734: Dimethyl 2,5-dichloro-4-bromo-3-oxopentanoate

Chemical compound data from PubChem database. IUPAC Name: methyl 4-bromo-2,5-dichloro-3-oxopentanoate. Molecular Formula: C6H7BrCl2O3. Molecular Weight: 277.92. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Inpatient Discharges (SPARCS De-Identified): Adult Prevention Quality Indicators (PQI) by Zip Code: Calendar Year 2015

This is one of two datasets that contain observed and expected rates for Agency for Healthcare Research and Quality Prevention Quality Indicators – Adult (AHRQ PQI) for calendar year 2015. This dataset is at the zip code level. The Agency for Healthcare Research and Quality (AHRQ) Prevention Quality Indicators (PQIs) are a set of population based measures that can be used with hospital inpatient discharge data to identify ambulatory care sensitive conditions. These are conditions where 1) the need for hospitalization is potentially preventable with appropriate outpatient care, or 2) conditions that could be less severe if treated early and appropriately. All PQIs apply only to adult populations (over the age of 18 years). The rates were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data and Claritas population information.
The observed rates and expected rates for each AHRQ PQI is presented by either resident county (including a statewide total) or resident zip code (including a statewide total).
Utah: 2011-2012 NSDUH

This report presents Utah\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 527255: 2,2,2-Trichloroethyl octanoate

Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl octanoate. Molecular Formula: C10H17Cl3O2. Molecular Weight: 275.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528662: Trimethylsilyl 7-[(trimethylsilyl)oxy]octanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 7-trimethylsilyloxyoctanoate. Molecular Formula: C14H32O3Si2. Molecular Weight: 304.57. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Close relationship of tissue plasminogen activator-plasminogen 
activator inhibitor-1 complex with multiple organ dysfunction syndrome 
investigated by means of the artificial pancreas

Background:
          Glucose tolerance (GT) has not been taken into consideration in 
investigations concerning relationships between coagulopathy and multiple organ 
dysfunction syndrome (MODS), and endothelial cell activation/endothelial cell 
injury (ECA/ECI) in septic patients, although coagulopathy is known to be 
influenced by blood glucose level. We investigated those relationships under 
strict blood glucose control and evaluation of GT with the glucose clamp method 
by means of the artificial pancreas in nine septic patients with glucose 
intolerance. The relationships between GT and blood stress related hormone 
levels (SRH) were also investigated.
        
        
          Methods:
          The amount of metabolized glucose (M value), as the parameter of 
GT, was measured by the euglycemic hyperinsulinemic glucose clamp method, in 
which the blood glucose level was clamped at 80 mg/dl under a continuous 
insulin infusion rate of 1.12 mU/kg per min, using the artificial pancreas, 
STG-22. Multiple organ failure (MOF) score was calculated using the MOF 
criteria of Japanese Association for Critical Care Medicine. Regarding 
coagulopathy, the following parameters were used: disseminated intravascular 
coagulation (DIC) score (calculated from the DIC criteria of the Ministry of 
Health and Welfare of Japan) and the parameters used for calculating DIC score, 
protein-C, protein-S, plasminogen, antithrombin III (AT-III), plasminogen 
activator inhibitor-1 (PAI-1), and tissue plasminogen activator-PAI-1 
(tPA-PAI-1) complex. Thrombomodulin (TM) was measured as the indicator of 
ECI.
        
        
          Results:
          There were no significant correlations between M value and SRH, 
parameters indicating coagulopathy and the MOF score. The MOF score and blood 
TM levels were positively correlated with DIC score, thrombin-AT-III complex 
and tPA-PAI-1 complex, and negatively correlated with blood platelet count.
        
        
          Conclusions:
          GT was not significantly related to SRH, coagulopathy and MODS under strict 
blood glucose control. Hypercoagulability was closely related to MODS and ECI. 
Among the parameters indicating coagulopathy, tPA-PAI-1 complex, which is 
considered to originate from ECA, seemed to be a sensitive parameter of MODS 
and ECI, and might be a predictive marker of MODS. The treatment for reducing 
hypercoagulability and ECA/ECI were thought to be justified as one of the 
therapies for acutely ill septic patients.
Compound 528695: Benzene, 2-(1,1-dimethylethyl)-1,4-dimethyl

Chemical compound data from PubChem database. IUPAC Name: 2-tert-butyl-1,4-dimethylbenzene. Molecular Formula: C12H18. Molecular Weight: 162.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527680: Butanoic acid, 2-chloro, 3-butenyl ester

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 2-chlorobutanoate. Molecular Formula: C8H13ClO2. Molecular Weight: 176.64. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399525-T1: [Translated] DENTAL WHITENING PRODUCT

The invention relates to light-activated teeth whitening compositions, and to the use thereof for lightening teeth. The inventive whitening agent contains riboflavin and or the derivatives thereof, which enable the oxidant in the whitening agent to decompose more rapidly, by means of radiation energy, thus effectively accelerating the whitening action. The invention especially relates to single-constituent or dual-constituent materials that have a stable pasty form and can be optionally additionally chemically activated.
Dynamic expression of a glutamate decarboxylase gene in multiple non-neural tissues during mouse development

Background
          Glutamate decarboxylase (GAD) is the biosynthetic enzyme for the neurotransmitter γ-aminobutyric acid (GABA). Mouse embryos lacking the 67-kDa isoform of GAD (encoded by the Gad1 gene) develop a complete cleft of the secondary palate. This phenotype suggests that this gene may be involved in the normal development of tissues outside of the CNS. Although Gad1 expression in adult non-CNS tissues has been noted previously, no systematic analysis of its embryonic expression outside of the nervous system has been performed. The objective of this study was to define additional structures outside of the central nervous system that express Gad1, indicating those structures that may require its function for normal development.
        
        
          Results
          Our analysis detected the localized expression of Gad1 transcripts in several developing tissues in the mouse embryo from E9.0-E14.5. Tissues expressing Gad1 included the tail bud mesenchyme, the pharyngeal pouches and arches, the ectodermal placodes of the developing vibrissae, and the apical ectodermal ridge (AER), mesenchyme and ectoderm of the limb buds.
        
        
          Conclusions
          Some of the sites of Gad1 expression are tissues that emit signals required for patterning and differentiation (AER, vibrissal placodes). Other sites correspond to proliferating stem cell populations that give rise to multiple differentiated tissues (tail bud mesenchyme, pharyngeal endoderm and mesenchyme). The dynamic expression of Gad1 in such tissues suggests a wider role for GABA signaling in development than was previously appreciated.
Purification and partial characterization of bacillocin 490, a novel bacteriocin produced by a thermophilic strain of

Background
          Applications of bacteriocins as food preservatives have been so far limited, principally because of their low antimicrobial activity in foods. Nisin is the only bacteriocin of significant use, but applications are restricted principally because of its very low activity at neutral or alkaline pH. Thus the isolation of new bacteriocins active in foods is desirable.
        
        
          Results
          We isolated a Bacillus licheniformis thermophilic strain producing a bacteriocin with some novel features, named here bacillocin 490. This bacteriocin was inactivated by pronase E and proteinase K and was active against closely related Bacillus spp. both in aerobic and in anaerobic conditions. Bactericidal activity was kept during storage at 4°C and was remarkably stable in a wide pH range. The bacteriocin was partially purified by elution after adhesion to cells of the food-isolated strain Bacillus smithii and had a rather low mass (2 KDa). Antimicrobial activity against B. smithii was observed also when this organism was grown in water buffalo milk.
        
        
          Conclusions
          Bacillocin 490 is a novel candidate as a food anti-microbial agent since it displays its activity in milk, is stable to heat treatment and during storage, is active in a wide pH range and has bactericidal activity also at high temperature. These features may allow the use of bacillocin 490 during processes performed at high temperature and as a complementary antimicrobial agent of nisin against some Bacillus spp. in non-acidic foods. The small size suggests its use on solid foods.
Medicaid Managed Care

The Medicaid Managed Care dataset uses CMS' state Transformed Medicaid Statistical Information System (T-MSIS) data for Arizona, Michigan, Nevada, and New Mexico to identify various metrics for managed care plans within each state. These metrics are designed to allow users to compare plans in each state across different specialty areas (currently Pediatric Dental, Behavioral Health, and Prenatal OB/GYN). This dataset does not include all available data in T-MSIS but utilized a subset to calculate the individual metrics identified.
Comparison of serum and bronchoalveolar lavage fluid sialic acid levels between malignant and benign lung diseases

Background
          It is known that tissue and serum sialic acid levels may be altered by malignant transformation. In this study, sialic acid levels were determined in bronchoalveolar lavage fluid (BAL) and serum in two groups of patients with lung cancer and non-malignant diseases of the lung.
        
        
          Methods
          Colorimetric methods were used for determination sialic acid in serum and in BAL samples. Flexible bronchoscopy was used to obtain the latter.
        
        
          Results
          Sialic acid levels in bronchoalveolar lavage fluid and serum did not show any statistically significant difference between subjects with malignant and the non-malignant lung diseases (p > 0.05). Sialic acid levels were also unrelated to the stage and localization of the tumor (p > 0.05).
        
        
          Conclusions
          Sialic acid levels do not appear to be a good marker for discriminating malignant from non-malignant diseases of the lung.
Compound 526687: (-)-Dehydroaromadendrene

Chemical compound data from PubChem database. IUPAC Name: 1,1,7-trimethyl-4-methylidene-4a,5,6,7,7a,7b-hexahydro-1aH-cyclopropa[e]azulene. Molecular Formula: C15H22. Molecular Weight: 202.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527432: (o-Methyl-Benzoyl)-phosphonic acid dimethyl ester

Chemical compound data from PubChem database. IUPAC Name: dimethoxyphosphoryl-(2-methylphenyl)methanone. Molecular Formula: C10H13O4P. Molecular Weight: 228.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
California (CA)

This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for California overall and for substate regions within California. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Information Memorandum (IM-83-04)

This Information Memorandum (IM) provides information for joint planning and submission of child welfare service plans for direct title IV-B grants to eligible indian tribes under section 428 of the Social Security Act. Effective June 24, 1993, the guidance in this IM has been superseded by ACYF-CB-PI-93-13.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 530323: 1-Penten-3-yl Acetate

Chemical compound data from PubChem database. IUPAC Name: pent-1-en-3-yl acetate. Molecular Formula: C7H12O2. Molecular Weight: 128.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526649: Cd(II) N,N-bis(2,2,2-trifluoroethyl)dithiocarbamate, chelate

Chemical compound data from PubChem database. IUPAC Name: N,N-bis(2,2,2-trifluoroethyl)carbamodithioate;cadmium(2+). Molecular Formula: C10H8CdF12N2S4. Molecular Weight: 624.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530738: m-Anisic acid, tridec-2-ynyl ester

Chemical compound data from PubChem database. IUPAC Name: tridec-2-ynyl 3-methoxybenzoate. Molecular Formula: C21H30O3. Molecular Weight: 330.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527302: 3-Phenyl-2-propen-1-yl heptanoate

Chemical compound data from PubChem database. IUPAC Name: 3-phenylprop-2-enyl heptanoate. Molecular Formula: C16H22O2. Molecular Weight: 246.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528342: Benzoic acid, 3,6-dichloro-2-hydroxy, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3,6-dichloro-2-trimethylsilyloxybenzoate. Molecular Formula: C13H20Cl2O3Si2. Molecular Weight: 351.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
The Siblings With Ischemic Stroke Study (SWISS) Protocol

Background
          Family history and twins studies suggest an inherited component to ischemic stroke risk. Candidate gene association studies have been performed but have limited capacity to identify novel risk factor genes. The Siblings With Ischemic Stroke Study (SWISS) aims to conduct a genome-wide scan in sibling pairs concordant or discordant for ischemic stroke to identify novel genetic risk factors through linkage analysis.
        
        
          Methods
          Screening at multiple clinical centers identifies patients (probands) with radiographically confirmed ischemic stroke and a family history of at least 1 living full sibling with stroke. After giving informed consent, without violating privacy among other family members, the proband invites siblings concordant and discordant for stroke to participate. Siblings then contact the study coordinating center. The diagnosis of ischemic stroke in potentially concordant siblings is confirmed by systematic centralized review of medical records. The stroke-free status of potentially discordant siblings is confirmed by validated structured telephone interview. Blood samples for DNA analysis are taken from concordant sibling pairs and, if applicable, from 1 discordant sibling. Epstein-Barr virus-transformed lymphoblastoid cell lines are created, and a scan of the human genome is planned.
        
        
          Discussion
          Conducting adequately powered genomics studies of stroke in humans is challenging because of the heterogeneity of the stroke phenotype and the difficulty of obtaining DNA samples from clinically well-characterized members of a cohort of stroke pedigrees. The multicentered design of this study is intended to efficiently assemble a cohort of ischemic stroke pedigrees without invoking community consent or using cold-calling of pedigree members.
Assessing the quality of reports of randomized trials in pediatric complementary and alternative medicine

Objective
          To evaluate the quality of reports of complementary and alternative medicine (CAM) randomized controlled trials (RCTs) in the pediatric population. We also examined whether there was a change in the quality of reporting over time.
        
        
          Methods
          We used a systematic sample of 251 reports of RCTs that used a CAM intervention. The quality of each report was assessed using the number of CONSORT checklist items included, the frequency of unclear allocation concealment, and a 5-point quality assessment instrument.
        
        
          Results
          Nearly half (40%) of the CONSORT checklist items were included in the reports, with an increase in the number of items included. The majority (81.3%) of RCTs reported unclear allocation concealment with no significant change over time. The quality of reports achieved approximately 40% of their maximum possible total score as assessed with the Jadad scale with no change over time. Information regarding adverse events was reported in less than one quarter of the RCTs (22%) and information regarding costs was mentioned in only a minority of reports (4%).
        
        
          Conclusions
          RCTs are an important tool for evidence based health care decisions. If these studies are to be relevant in the evaluation of CAM interventions it is important that they are conducted and reported with the highest possible standards. There is a need to redouble efforts to ensure that children and their families are participating in RCTs that are conducted and reported with minimal bias. Such studies will increase their usefulness to a board spectrum of interested stakeholders.
Compound 527328: Methyl 2-[3-(trifluoromethyl)anilino]nicotinate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylate. Molecular Formula: C14H11F3N2O2. Molecular Weight: 296.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528177: 1,3-Cyclopentadiene, 2-heptyl

Chemical compound data from PubChem database. IUPAC Name: 2-heptylcyclopenta-1,3-diene. Molecular Formula: C12H20. Molecular Weight: 164.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2011 CMHS Uniform Reporting System (URS) Output Tables for Michigan

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E400995-T1: [Translated] DEVICE FOR STIMULATING AN UDDER DURING A MILKING PROCESS

The invention relates to a device for stimulating an udder during milking, made up of a housing with a first connection (350, 351) and a second connection (352, 353), which housing can be grasped by a hand. The first connection connects the housing to a pulsator and the second connection connects the housing to a teat cup. A throttle valve (305, 306) is interposed between the first connection and the second connection. A control device (309) is housed in the housing and is adapted to bring the throttle valve, after a defined duration, from a partially open to an open position.